Tecovirimat Resistance in Mpox Patients, United States, 2022–2023

During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Todd G., Gigante, Crystal M., Wynn, Nhien T., Matheny, Audrey, Davidson, Whitni, Yang, Yong, Condori, Rene Edgar, O’Connell, Kyle, Kovar, Lynsey, Williams, Tracie L., Yu, Yon C., Petersen, Brett W., Baird, Nicolle, Lowe, David, Li, Yu, Satheshkumar, Panayampalli S., Hutson, Christina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683829/
https://www.ncbi.nlm.nih.gov/pubmed/37856204
http://dx.doi.org/10.3201/eid2912.231146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683829/
https://www.ncbi.nlm.nih.gov/pubmed/37856204
http://dx.doi.org/10.3201/eid2912.231146

Ejemplares similares